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ABSTRACT
Spray drying is a promising method for the stabilization of vaccines, which are usually formulated as
liquids. Usually, vaccine stability is improved by spray drying in the presence of a range of excipients.
Unlike freeze drying, there is no freezing step involved, thus the damage related to this step is avoided.
The edge of spray drying resides in its ability for particles to be engineered to desired requirements, which
can be used in various vaccine delivery methods and routes. Although several spray dried vaccines have
shown encouraging preclinical results, the number of vaccines that have been tested in clinical trials is
limited, indicating a relatively new area of vaccine stabilization and delivery. This article reviews the
current status of spray dried vaccine formulations and delivery methods. In particular it discusses the
impact of process stresses on vaccine integrity, the application of excipients in spray drying of vaccines,
process and formulation optimization strategies based on Design of Experiment approaches as well as
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Introduction
Many vaccines are inherently unstable in liquid form because
they are prone to chemical and physical degradation,1 making
it difficult to achieve an adequate shelf life or prevent the need
for a cold chain. Although many factors contribute to vaccine
degradation, temperature instability is likely to be the most rel-
evant.2 For this reason, almost all liquid vaccines require the
cold chain to ensure vaccine stability. This usually requires
keeping vaccines at 2–8 C during storage and transport.3
Maintenance of the cold chain is challenging, especially in
developing countries, where vaccines are needed the most.4
The cold chain also contributes to the financial burden of vacci-
nation programs. According to the World Health Organization,
approximately half of supplied vaccines are wasted due to cold
chain disruption, which has a detrimental effect on vaccination
programs.5
The stability of vaccines may be improved by optimizing the
composition of the vaccine matrix, i.e. the formulation. Through
removal of water, vaccine stability can be increased due to
decreased mobility and the prevention of degradation pathways
that are facilitated by water.6 Dry vaccine formulations are gener-
ally less sensitive to temperature induced degradation. This
makes these vaccines less dependent on the cold chain, thereby
improving cost effectiveness of vaccination programs by reducing
vaccine wastage.4 Additionally, dried vaccines may attain an
extended shelf life, which holds great potential for stockpiling in
case of pandemics or bioterrorism threats.7
There are several methods available to dry vaccines.8 Freeze-
drying is commonly used for drying of vaccines on an
industrial scale. It involves freezing of a liquid solution followed
by removal of water by sublimation of ice and thereafter by
desorption of remaining water at low pressure and higher tem-
perature. This results in a dried cake in the final container and
requires reconstitution before administration.9
Spray drying, an alternative to freeze-drying, is well estab-
lished to produce dried biologics. Spray drying has the advan-
tage over freeze-drying that no freezing or high vacuum is
involved. As a result of being a one-step drying process, spray
drying consumes less energy compared with lyophilization
which results in lower operating costs.10 Spray drying results in
a dispersed fine powder compared with a dry cake as obtained
by conventional freeze-drying. This may enable further powder
handling and can be delivered without reconstitution to for
example mucosal routes of administration. Mucosal powder
vaccine delivery, e.g. via the respiratory tract, may induce
mucosal immunity at the port of entry of the pathogen, poten-
tially providing additional protection compared with parenteral
vaccine delivery. Spray drying being a continuous drying pro-
cess, serves as an attractive method to produce bulk powder
vaccines. Yet it does have some drawbacks. Antigen is exposed
to shear stress during atomization, and elevated temperatures
during drying, further formation of air-water interfaces during
droplet formation might lead to antigen denaturation. This is
addressed in further section. Additionally, a secondary drying
step may be required when a very low residual moisture con-
tent is desired in the end product. This may reduce the time
and energy savings for spray drying as compared with freeze-
drying.
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In this review, we discuss the current status and novel devel-
opments of spray drying as a method for drying vaccines. Fur-
thermore, spray drying process optimization strategies based
on Design of Experiment approaches are addressed. Finally, the




Spray drying is a single step drying process that converts a liq-
uid feed into fine dispersible particles, with controlled physio-
chemical and morphological characteristics.11 It has gained
significant attention in formulating dried vaccines for its ease
of use and potential for simple scale-up.12
The drying process can be divided into 3 phases (Fig. 1). The
process begins with the nebulization of liquid feed (liquid con-
taining vaccine and excipients), generating an aerosol, into a
heated gaseous drying medium. There are 3 types of spraying
flow patterns that can be applied depending on the direction in
which the air and liquid enter the drying chamber: counter cur-
rent, co-current and mixed flow. Considering most vaccines are
heat sensitive biologics, it is crucial to use the co-current drying
mode. In this mode, the wettest aerosol droplet comes in
contact with highest air temperature and driest particles with
the lowest temperature, minimizing the risk of heat damage to
vaccine. The drying temperature is determined by the inlet air
temperature which ranges from 60 to 220 C for a laboratory
scale dryer. During the initial phase of drying, solvent starts to
evaporate immediately. As the microenvironment surrounding
the droplet gets saturated an equilibrium state is attained
between vaccine droplet and drying air. The evaporation at this
point is characterized by constant drying rate, where the tem-
perature of the particle is defined by the wet bulb temperature.
Once saturation conditions on the vaccine droplet surface can
no longer be maintained due to diminishing water content, the
secondary drying phase begins that is marked by a falling water
content of the droplet/particle. As the droplet shrinks, the dis-
solved material concentrates at the surface, forming a solid
layer around the droplet. Following this, further solvent evapo-
ration occurs through the dried surface layer.
Heating and evaporation of water from the vaccine contain-
ing droplets could reversibly or irreversibly affect the antigen
due to alteration in secondary structure, pH shifts and precipi-
tation of active ingredient while exceeding the solubility limit
as also observed in lyophilization.13 However, the self-cooling
effect of droplets during evaporation prevents the temperature
increase of droplet surface above the wet bulb temperature.14
For a more detailed description on evaporation and particle
Figure 1. Overview of spray drying process [Adapted from Kanojia et al. (reference 11)] . The liquid vaccine excipient mixture enters the nozzle along with nitrogen via 2
different inlets. The mixing of liquid and nitrogen occurs just before end of the nozzle resulting in formation of aerosols. The heating mantle is located around the nozzle
and the actual temperature is displayed on the equipment control panel (not shown). The dried particles enter the cyclone, following the airflow as depicted due to the
special design of the cyclone. The nitrogen is separated, filtered and dehumidified before re-circulating back into the system and powder ends up in the collection vessel.





































formation, the reader is referred to the publication of Vehr-
ing.15 It is a good practice to use a lower inlet air temperature
to reduce potential thermal stress to the vaccines. Depending
on the capacity of spray drier and airflow rate, the drying pro-
cess may take between 0.2 and 30s per droplet.16 The large sur-
face area of aerosol formed during spray drying and large
volume of drying gas ensures such a rapid drying process.
Finally, the dried particles are separated from the process gas
stream using either cyclone separators or baghouse filters. Most
commonly used are the cyclone separators, the principle of
which is based on the density difference between particle and
drying gas. Bag filters use the concept of impaction onto a filter
or electrostatic precipitation. The drying gas is released into the
environment in an open system, or filtered, dehumidified
and returned to the drying unit in a closed system. The sepa-
rated bulk vaccine powder can be stored as bulk powder or ali-
quoted in different single or multidose containers under
controlled conditions. One can further process bulk vaccine
powder for additional drying (if required to reduce the residual
moisture content), encapsulation or coating with other
excipients.17
Variants in spray drying technique
Spray drying technology exists as several variations, each with
pros and cons. The variants includes spray freeze drying and
supercritical drying using CO2 assisted nebulization.
Spray freeze drying
Spray freeze drying technique incorporates aspects of both
spray drying and freeze-drying. The process includes atomiza-
tion (droplet generation), freezing and sublimation drying. In
Spray freeze drying a liquid feed (excipient vaccine mixture) is
directly atomized into a cryogenic medium, instead of a heated
gaseous medium as in spray drying. This leads to rapid freezing
of the droplets, which are later dried by sublimation, identical
to the freeze-drying process.18 This allows processing of
extremely heat sensitive antigens. In addition, spray freeze dry-
ing has an advantage over freeze-drying in preparation of dry
alum adjuvant containing vaccines. Alum is sensitive to freez-
ing and tends to agglomerate during freeze-drying. Maa et al. 19
showed that by spray freeze drying it is possible to limit the
alum particles aggregation with no loss in adjuvant activity.
However, during the freezing step, degradation of antigen due
to exposure to ice surfaces is possible.
Several vaccine candidates have been successfully spray
freeze-dried. This includes spray freeze-dried powder for Influ-
enza vaccine 20-22; alum adsorbed diphtheria, tetanus and hepa-
titis B vaccine;19,23,24 anthrax vaccine,25,26 and plague vaccine.27
Carbon dioxide-assisted nebulization with bubble drying
Super critical drying involves the use of carbon dioxide or
nitrous oxide in their supercritical fluid state to aid the drying
process. Generally, the protein solution is mixed with the
supercritical fluid before atomization and then sprayed under
atmospheric condition. The setup is similar to that used for a
typical spray drying process. The supercritical fluid is used as
an antisolvent that causes precipitation of the protein. The liq-
uid evaporation occurs in the supercritical region, where the
distinction between gas and liquid ceases to apply. Jovanovic
et al.28 have summarized the narrower literature regarding the
stabilization of proteins and drying by supercritical drying.
Carbon dioxide-assisted nebulization with bubble drying
(CAN-BD) is based on the concept of supercritical
drying, patented by Sievers et al..29,30 It involves mixing and
dissolution of CO2 within the aqueous vaccine excipient solu-
tion under supercritical conditions (pressure and temperature
usually between 8–10 MPa and 30–50C).31,32 The pressurized
mixture is released as a spray through a nozzle, the rapid
decompression of liquid mixture and expansion of compressed
CO2 results in fine spray of droplets. This aerosol is dried rap-
idly by heated gas (generally nitrogen, around 25 to 65 C) into
micron size particles. CO2 is used as an aerosolizing aid that
permits drying at lower temperature unlike spray drying, which
may favor drying of thermosensitive vaccines. However, the
high pressure requirement may impact the antigen stability and
dissolution of CO2 may result in pH fluctuations (decrease
toward acidic pH), if not properly controlled. Vaccines that are
produced by CAN-BD include live attenuated measles vac-
cine,33,34 and hepatitis B surface antigen protein.31
Impact of process stress on vaccine quality
Shear stress may occur when the vaccine-excipient liquid mix-
ture is atomized into small droplets, resulting in possible reduc-
tion or loss of antigen activity. Thompson et al. 35 observed a
loss of 2 log titers when increasing the atomization pressure
from 250 to 450 Ls/hour for a spray dried adenoviral vector
vaccine. In addition, the choice of nozzle used for atomizing
during spray drying can play a crucial role in causing shear
stress. Grasmeijer et al. 36 demonstrated that during spray dry-
ing of a shear sensitive protein lactate dehydrogenase (LDH),
the choice of nozzle had a significant influence on recovery of
functional protein. A loss of 37% of LDH activity was observed
during atomization with ultra-sonification nozzle compared
with 9% loss in activity using a 2-fluid nozzle. The shear stress
experienced by vaccines if needed, could be overcome by mod-
ulating the atomization pressure, solution feed rate, solution
viscosity or use of stabilizers.37 Optimal selection of these
parameters can help in minimizing shear stress induced
degradation.
Dehydration stress in combination with adsorption to air-
liquid interface may result in protein denaturation and subse-
quent aggregation, resulting in partial or complete loss of activ-
ity.38,39 The hydrophobic protein residues align themselves
toward the air-liquid interface, formed after atomization. Inter-
action among these protein residues during drying, might result
in aggregation and finally precipitation. Use of surfactants or
proteins can reduce process loss and may increase the stability
of vaccines during spray drying.40
The temperatures experienced by the particle containing
antigen in the late drying phase is close to the outlet tempera-
ture 41 and can vary based upon the selected inlet temperature
of the drying gas, feed flow rate and drying airflow rate. The
inlet air temperature, being the central component, directly
influences the outlet temperature. Moreover, the evaporation
rate has an impact on particle characteristics and thus variables
important for evaporation are also important for powder end





































product characteristics.42 As described previously in the process
principle, the vaccine droplets experience temperatures equiva-
lent to the wet bulb temperatures during the constant drying
phase. Nevertheless, the thermal stability is antigen dependent.
Therefore, one needs to carefully optimize the drying condi-
tions to attain a dry powder with low moisture content without
adversely affecting its activity. Apart from the above mentioned
factors, individual process parameters may be critical and can
be adjusted in the spray drying process. These include drying
air temperature, atomization process (e.g., droplet size, spray
rate, spray mechanism) and airflow rate.11,15,43,44 Considering
the heterogeneous nature (live attenuated, inactivated or sub-
unit) of vaccines, optimal drying requires a careful optimization
of the drying process parameters of each individual vaccine. In
addition, the presence of oxygen, the storage temperature, the
water activity, the relative humidity and exposure to light are
factors that may influence the shelf life of dried vaccine pow-
ders and they require careful consideration. Table 1 summa-
rizes the role of different process parameters and their
influence on product characteristics in context of different
stress factors. For a more detailed description on influence of
process parameters on spray dried vaccine powder characteris-
tics, the reader is referred to work of Kanojia et al.11
Impact of formulation parameters on vaccine quality
Sugars and polysaccharides
Sugars (trehalose, sucrose, inulin etc.) are the most commonly
used stabilizing excipients for spray drying of vaccines (sum-
marized in Table 2). There are 2 major theories explaining their
protective mode of action.66 Immobilization of vaccine antigen
in an amorphous sugar glass matrix during drying is portrayed
by the vitrification theory.67 Drying of vaccines in the presence
of sugars can yield both amorphous and crystalline powders,
based on their glass transition temperature (Tg).
68 In a glassy
state, sugars exhibit high viscosity and as a result molecular
mobility of protein is restricted.69 The transition from this
glassy state to the undesirable rubbery state occurs at the Tg.
Excipients with low Tg tend to crystallize upon spray drying
and absence of an amorphous matrix destabilizes the protein.
Thus, selection of right excipient with appropriate Tg can influ-
ence antigen stability during drying and further storage. As a
rule of thumb the Tg should be well above the storage tempera-
ture to accommodate storage stability of proteins.66 The other
hypothesis is based on the theory that integrity of proteins in
hydrated state is sustained by hydrogen bonding with water
molecules. Upon drying, the bonding is replaced with hydrogen
bonds between sugar and protein, thereby maintaining protein
integrity.70 This also may be the case for viral or bacterial mem-
branes. Research from Muttil et al. 71 suggested formation of
hydrogen bonds between hydroxyl group of the sugars and the
phosphate group in the lipid bilayer of live attenuated Listeria
monocytogenes during spray drying. Furthermore, to maximize
the hydrogen bonding with a protein, the sugar molecule
should firmly fit the irregular surface of the protein. This can
be achieved more easily in the amorphous state of the sugar
rather than the crystalline state. Additionally, the molecular
weight of the sugar influences the hydrogen bonding ability
between protein and sugar molecules during drying. Grasmeijer
et al. 66 described that trehalose, with its lower molecular
weight, formed more hydrogen bonds and fitted better to the
irregular surface of the protein compared with inulin, a higher
molecular weight sugar, during spray drying. The relevance of
the carbohydrate flexibility was further described by Tonnis et
al..72 Nevertheless, considering the heterogeneous nature of the
vaccines, it is difficult to envisage stabilization with only one of
above illustrated theories and interaction between these mecha-
nisms may be relevant for stabilization by sugars and polysac-
charides. In addition, often other type of excipients, such as
surfactants and divalent ions, have to be included to provide
enough stabilization.
Surfactants
Surfactants may reduce the surface tension of atomized drop-
lets during drying and compete with the vaccine antigen for the
surface at the air liquid interface. They are composed of hydro-
philic and hydrophobic regions, and their action is presumed
to be mediated by direct interaction with both the proteins and
interfaces.73-75 They are used to prevent and reduce the forma-
tion of protein aggregates. Pluronic F68, a mild non-ionic sur-
factant, was successfully used for spray drying of a live
attenuated measles vaccine 40 and a live attenuated influenza
vaccine.46 These studies illustrate that surfactants compete with
the antigen for the surface to reduce shear stress and providing
stability during atomization and drying. However, the amount
of surfactants should be carefully optimized. Indiscriminate use
of surfactants with vaccines containing bacteria or viruses could
disrupt the membrane. This was observed with hepatitis B virus
inactivation 76 and various bacterial strains 77 by using Tween
80 or Tween 20.
Divalent ions
Divalent cations improve the stability of several viruses. MgCl2
(divalent magnesium ion) has been used as an effective stabi-
lizer of the liquid live attenuated oral polio vaccine.78 A study
from Chen et al. 79 describes that MgCl2 stabilizes poliovirus
conformation by specific ionic interaction with capsid and by
preventing water penetration into the capsid, thus reducing
capsid swelling. Other studies have also suggested the stabiliza-
tion of rotavirus,80,81 and adenovirus 82 by divalent cations
occur through stabilization of the viral capsid. A combination
of Zn2C and Ca2C improved the storage stability of a spray
dried live attenuated measles vaccine by 1 log TCID50 when
Table 1. Spray drying process parameters affecting product characteristics. The
process parameters influence different stress factors experienced by the antigen.
Shear stress (z), heat stress () and dehydration stress (y).
Process parameter Parameter/dependence
Atomization flow ratez Particle size, antigen stability
Feed flow ratey Outlet temperature, residual
moisture content
Inlet air temperaturey Outlet temperature, residual
moisture content, antigen
stability
Drying airflow ratey Outlet temperature, residual
moisture content
Formulationy/ Solid concentrationy Particle size, morphology,
density, residual moisture
content, antigen stability







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































stored for 1 week at 37C.40 Ohtake et al. 40 hypothesized that,
Zn2C and Ca2C interact with the membrane lipids and proteins.
The exact nature of this cation-viral molecule interaction is not
clearly understood. However, the suggested interaction may
preserve the conformation of the proteins, thereby aiding integ-
rity of viral structure during processing. Since the core genetic
material is surrounded by a viral envelope instead of a capsid in
measles virus, as opposed to rotavirus and adenovirus, which
are non-enveloped viruses, the exact nature of interaction needs
further investigation.
Proteins
Proteins such as albumin have been regularly used to stabilize
vaccines. Human serum albumin (HSA) was used in the formu-
lation of spray dried measles vaccine.40 HSA improved the stor-
age stability by 0.8 log TCID50 compared with the formulation
without HSA, when stored for 4 weeks at 37C. The mode of
action could be explained by different mechanisms. Large
molecular components like proteins may slow down the migra-
tion of antigen to the air-liquid interface during droplet drying.
Thus, after drying the vaccine component is concentrated into
the core of the dried particle, minimizing the interaction with
moisture during storage. Moreover, inclusion of protein com-
ponents elevates the Tg of the formulation,
83,84 thereby improv-
ing storage stability. In addition, the stabilizing effect could be
explained by increased interaction of the stabilizing protein
with the vaccine particle, i.e., particle coating and surfactant
like surface enrichment of antigen with protein.85
Polymers
Besides the excipient groups mentioned above, various studies
have reported the use of enteric coating polymers such as
Eudragit L30 D-55 and FS 30D, cellulose acetate phthalate,
hydroxyl propyl methyl cellulose acetate succinate and poly lac-
tic-co-glycolic acid as an encapsulating polymer for spray dried
vaccines.51,54,59,64 These polymers are soluble at pH 5.5 and
above; thus, can provide protection to antigens in the enteric
environment. This provides a great potential for vaccines to be
delivered via the oral route, which is further discussed in the
delivery section.
Implementing design of experiment approach to spray
dried vaccines
As outlined above, spray drying consists of a substantial num-
ber of both process and product variables that can be fine-
tuned for optimal results. A broader application of spray dry-
ing, would require a thorough understanding of critical process
parameters and critical product characteristics of the dried vac-
cine products. Optimization through an OFAT (one-factor-at-
a- time) approach is resource and time consuming when
attempting to establish the (sub) optimum. Moreover, the pres-
ence of complex biologics like vaccines makes the process opti-
mization more arduous.86 A Design of Experiments (DoE)
approach can be used instead to systematically study the effects
of multiple factors on a certain parameter using strategically
planned combinations of variables and subsequent statistical
analysis. DoE can be used to identify critical and non-critical
parameters, and their respective interactions, of a production
process. Furthermore, it can be used to quantify the impact of
raw materials (excipient combination and vaccine) and process
parameters on the product characteristics and quality. There-
fore, with DoE one can obtain more valuable information with
fewer experiments, compared with an OFAT approach. Several
studies have used a DoE approach to investigate and optimize
the spray drying process for vaccines, including influenza,11
human papillomavirus 55 and human type 5 adenoviral vector
(AdHu5 encoding LacZ).35 Kanojia et al. 11 obtained a design
space for spray dried inactivated influenza vaccine, substantiat-
ing the interplay of process parameters (e.g., inlet air drying
temperature, liquid feed flow rate, atomization pressure) and
how they affect the dried product characteristics (e.g., vaccine
antigenicity, powder particle size, residual moisture content,
process yield). Muttil et al. 55 used a DoE approach to optimize
the excipient composition for a spray dried formulation con-
taining virus like particles against human papillomavirus. The
powder containing virus like particle stored at 37 C for 12
months when intramuscularly (i.m.) administered in mice eli-
cited comparable IgG titers as liquid vaccine administered by
the i.m. route. The design space was used to understand the
interaction of excipients concentration and process parameters
(inlet air drying temperature, liquid feed flow rate, atomization
pressure) to optimize powder yield, moisture content and parti-
cle size. Other studies from Thompson et al. 35 optimized spray
drying process conditions, to decrease loss in viral activity for
an adenoviral vector vaccine during drying.
Utilization of DoE in spray dried vaccines is limited to only
the few aforementioned studies. However, an increase in use of
DoE approach is expected, driven by both regulatory authori-
ties and industry. There are FDA guidelines for quality man-
agement of biologicals like vaccines described in Q10.87
Compliance with these regulations and implementing DoE dur-
ing early stages of the development of a spray dried vaccine
would help regulatory agencies expedite the approval pro-
cess.88,89 Additionally, DoE can provide a robust process, which
can lead to fewer manufacturing deviations or failures.90
Current state of experimental spray dried vaccines
A number of publications have described spray drying as a suit-
able method for drying vaccines (Table 2). The table describes
vaccines and their subtypes (live attenuated or inactivated), key
excipients used, process conditions and the key outcomes. To
date, there are no marketed spray dried vaccines. However, sev-
eral spray dried vaccines are in the pipeline and some are in
early clinical trials.
Ohtake et al. 40 produced a relatively stable spray dried live
attenuated measles vaccine, with only a minor process loss. The
formulation contained trehalose and sucrose, surfactant Plur-
onic F68 along with L-arginine, human serum albumin and
combinations of divalent ions as the key stabilizers. However,
the formulation without Pluronic performed better during stor-
age at 37 C for 8 weeks in terms of vaccine stability (0.9 log
loss without surfactant and 1.2 log loss with surfactant. The
measles spray dried (carbon dioxide assisted nebulization with
a bubble dryer) vaccine for pulmonary administration (particle
size: 3–5mm), was the first spray dried vaccine to enter phase I
clinical trial showing promising results.91 The study used a





































spray dried live attenuated measles vaccine with myo-inositol
as the stabilizer, substituting sorbitol used in the lyophilized
marketed formulation (keeping all other excipients). The vac-
cine experienced 0.6 log loss in its viral activity during drying
and surpassed the WHO stability requirement for freeze-dried
measles vaccine (less than 1 log loss in viral activity after 1
week storage at 37C). This formulation has also been previ-
ously prepared by Burger et al..33 The clinical study in healthy
adults showed a comparable immune response to that of subcu-
taneously administered (same dose of) licensed vaccine (recon-
stituted lyophilized powder). Two experimental dry powder
inhalers PuffHaler and SoloventTM were used to administer
the vaccine powder. Powder delivery through these devices has
been described in a chapter from Weninger et al..92Measles
powder vaccine has shown the potential to be the first spray
dried vaccine in the market in future.
There are several spray dried vaccine candidates in pre-clini-
cal studies (Table 2). Lovalenti et al. 46 showed that formula-
tions containing low concentrations of Pluronic F68 had lower
process loss than formulation without (0.8 § 0.4 versus 1.2 §
0.4 log TCID50, respectively) suggesting that surfactant in the
formulation could provide a shielding effect from destabilizing
stresses on live attenuated influenza vaccine during spray dry-
ing. The immunogenicity was comparable to liquid control
when intranasally administrated (after reconstitution) in fer-
rets. Sou et al. 47 prepared spray dried whole inactivated virus
(WIV) influenza vaccine with trehalose and leucine as stabiliz-
ing excipients. The results indicate that administration of pow-
der by the pulmonary route showed stronger induction of
mucosal and systemic immune response compared with that of
subcutaneously administered liquid vaccine. Saluja et al. 21
describe a relatively simple formulation for influenza subunit
vaccine that provides full stabilization of the vaccine for at least
3 y at room temperature. Another study from Kanojia et al. 11
describes spray drying of thermostable whole inactivated influ-
enza vaccine described the use of Design of Experiment
approach to optimize the spray-drying process. The main find-
ing of this study are summarized in the Design of Experiment
section. These results underscore the potential of spray dried
influenza vaccines to pitch a thermostable, effective and afford-
able influenza vaccine candidate for future clinical studies.
Immunization with inhalable BCG vaccine powder has
shown to significantly reduce the bacterial burden in guinea
pigs, compared with animals immunized with parenteral BCG
when challenged with Mycobacterium tuberculosis.48 A recent
phase I clinical study detected antigen specific CD4 T cells in
bronchoalveolar lavages after immunization with an pulmo-
nary aerosol liquid TB vaccine candidate (MVA85A), showing
no systemic adverse events.93 These results reassured the safety
and better efficacy of the pulmonary route for the delivery of
MVA85A vaccines, and thus powder MVA85A vaccine 51,52
could be a potential candidate for future clinical studies.
Another study with a spray dried bacterial vaccine used a poly-
mer encapsulated Vibrio cholera.59 Heat inactivated Vibrio
cholera was spray dried with cellulose acetate phthalate and
alginate, and was administered as an oral suspension in rats
eliciting IgG and IgM responses comparable to orally adminis-
trated liquid Vibrio cholera. In another study,94 Eudragit
encapsulated Vibrio cholera microparticles, were shown to be
antigenically stable when stored for 6 months at 40C. These
are promising results for the development of an oral spray dried
vaccine with an extended shelf life. Several other studies on
spray dried diphtheria, anthrax and hepatitis B vaccine are out-
lined in Table 2, showing the potential of spray drying in vac-
cine development.
Delivery of spray dried vaccines
Dry powder vaccine formulations produced by spray drying
provide an opportunity for the combination of both improved
antigen stability and alternative routes of administration for
the vaccine. Various groups are researching the delivery of
spray dried vaccines via pulmonary, mucosal, skin and oral
routes.17,45,48,53,91 Production of controlled engineered particles
of desirable size range gives spray drying the flexibility to pro-
duce powder antigens that can be administered via diverse
routes of administration. The scope of delivery via different
routes is described in the following sections.
Pulmonary delivery
Inhalable dried particles are distributed in the respiratory tract
based on their aerodynamic particle size. In humans particles
with aerodynamic diameter between 5–3 mm are best suited for
delivery to the airways. Smaller particles, with an aerodynamic
diameter of 1–3 mm are used for deep lung delivery.10 Minne et
al. 95 showed the influence of the site of deposition of the anti-
gen on the immune response in mice. They observed better sys-
temic, local and cellular immune responses when the influenza
split virus vaccine was deposited to the deeper lung areas than
when the vaccine was targeted to the upper airways. Given that
many pathogens like influenza, tuberculosis or measles invade
the host via mucosal membranes, non-invasive delivery of vac-
cine antigens would provide more local and direct protection at
the site of infection.96 In addition, the large surface area, exten-
sive vascularization and thin epithelium in alveolar region facil-
itates efficient delivery of antigen. Moreover, it has been
suggested that dry particulate antigens, as opposed to dissolved
antigens, are better taken up by the antigen presenting cells
leading to a more powerful immune response.97-99
Dry powder inhalers incorporate the advantage of stable
vaccine formulations with rapid delivery and high lung deposi-
tion depending on the particle dynamics and fluid dynamics in
the respiratory tract.100 Two experimental dry powder inhalers,
PuffHaler and Solovent (Becton Dickinson) (Fig. 2a and 2b)
have been used for delivery of powder measles vaccine in adults
males (18 to 45 y age).91 Delivery by either PuffHaler or Solo-
vent had a safety (no serious adverse events) and immunoge-
nicity profile (measles IgG antibodies and measles specific
neutralizing antibody titers) comparable to that of licensed
measles vaccine delivered by the subcutaneous route. Each
device disperses powder vaccine into an inexpensive, single-
use, disposable reservoir from which the patient inhales, elimi-
nating the risk of cross-contamination.92 Another prototype
device is a single use disposable inhaler, the Twincer (Univer-
sity of Groningen, Fig. 2c). The simple design reduces the pro-
duction costs, as the 3 plate-like parts (with blister) can simply
be stacked and clicked together.101 Boer et al. 102 have shown





































that due to high de-agglomeration efficacy of Twincer, a pow-
der dose of 25 mg can be effectively de-agglomerated and dis-
persed for inhalation (when tested in vitro). Cyclops, a
modified version of the Twincer inhaler, was used to evaluate
safety and pharmacokinetic parameters of powder tobramycin
in patients with cystic fibrosis.103 This study illustrated the effi-
cacy of the device to deliver powder efficaciously via pulmonary
route and can be potentially used to deliver powder vaccines via
the pulmonary route, with a future to enter the market. Thus,
the use of these portable single-use devices and possibility of
self-administration of powder vaccine reduces the need of
trained healthcare workers. Furthermore, it offers a solution for
vaccination of people who suffer from needle-phobia.
Intranasal delivery
The nasal cavity and its associated lymphoid tissue, are an
excellent site for vaccine delivery,104 although there are con-
cerns with regard to possible interaction with the olfactory bulb
and other neuronal tissues.105 Because there is a non-ciliated
area in the anterior part and ciliated area in the posterior part
of the nasal cavity, the site of deposition of vaccine in the nose
is crucial considering the mucociliary clearance of the vaccine
from the nose.106 The deposition site is determined by the
size of the dried particle and velocity at which the delivery
device releases the particles in the cavity.107 For aerosols or par-
ticles larger than 50 mm, intra nasal (i.n.) delivery is reproduc-
ible and independent of the vaccine recipient’s breathing. This
is because the site of deposition is governed by inertial
impaction (bigger particles collide with the nasal mucosa rather
than follow the streamline direction of the inhaled air).108 Chi-
tosan, an additive with mucoadhesive properties, facilitates
antigen binding with the mucosal epithelial surfaces.109 Huang
et al. 110 showed that a chitosan containing anthrax vaccine
powder formulation with 10 mg of recombinant Protective
Antigen (rPA), when delivered intranasally with a specially
designed device, as described previously,111 elicited protective
immune responses in rabbits. The protection against the spore
challenge was improved for powder vaccinated rabbits when
compared with one with liquid formulation (10 mg rPA)
administered by MicroSprayer devices (PennCentury).
In general, particles designed for nasal delivery should be
large enough to impact in the nasal cavity with minimal deposi-
tion in the pulmonary airway. A study from Garmise et al. 112
produced powder with a target volume median diameter of
26.9 mm for i.n. influenza vaccination in rats. Intra nasal
immunization with vaccine powder generated equivalent serum
IgG titers as liquid vaccine administered intranasally. Also, the
nasal IgA titers were comparable between powder and liquid
formulations. An investigational device, is developed by CDC
and Creare, an engineering services company, for administra-
tion of dry-powder vaccine via nasopharyngeal tissues.113 It
operates by exhalation through the mouth, blowing the powder
into the nose while simultaneously generating air flow that lim-
its entry to the lower respiratory tract. While several studies
have shown the proof of concept for intranasal powder vaccina-
tion, clinical studies are needed for demonstrating safety and
efficacy of i.n. powder vaccination in humans. The device
Figure 2. Pulmonary delivery of spray dried powders (Adapted from references 89 and 99, with permission from Elsevier). A. PuffHaler Device (AktivDry LLC, USA): Air
from the activation bulb lofts vaccine powder from the disperser into the reservoir once the pressure threshold of the burst valve is exceeded. The reservoir filled with
powders are directly inhaled through a mouthpiece with adults and adolescents or mask (not shown) placed over the nose and mouth with infants and young children.
B. SoloventTM Device (Becton, Dickinson & Company, USA): Air from the activation syringe ruptures the membrane of the vaccine capsule, releasing vaccine powder in to
the reservoir. Patient inhales it through the mask. C. Twincer (University of Groningen, The Netherlands): A dry powder inhaler for pulmonary delivery. The vaccine powder
is placed between the plates in an aluminum blister for moisture protection. The powder can be made available for inhalation by removal of a pull off blister strip.





































cannot be used by very young children, limiting its use in pedi-
atric vaccination programs.
Buccal and sublingual delivery
The buccal region is an attractive site for delivery of vaccine
antigens. Langerhans and dendritic cells which are superficially
present under the oral mucosal epithelium, act as an important
target for induction of immune responses.114 Also, it is sug-
gested that the efficiency of vaccine delivery via this route is
directly related to the permeability of the mucosal membranes
(thickness buccal mucosa around 500–800 mm and sublingual
region around 100–200 mm).115 Several groups are developing
dosage forms for optimizing sublingual and buccal delivery of
vaccines.116 Gala et al. 17 produced spray dried microparticles
(particle size »3 mm) using bovine serum albumin and glutar-
aldehyde, containing live attenuated measles vaccine. These
particles were incorporated into an oral disintegrating film
(ODF) and administered to pigs via the buccal route, eliciting
IgG responses in serum when compared with pre-dosing IgG
responses. ODF with vaccine containing microparticles in
which the polymer matrix protects the antigen in a stable form,
offer a great platform for efficient and non-invasive delivery of
vaccines. Adjuvants can also be co-encapsulated, in the micro-
particles along with vaccine, during spray drying. These micro-
particles were found to induce IL-8, IL-1 and TNF in an
in vitro system.117
Skin delivery
Ease of access and existence of a large number of antigen pre-
senting cells make the skin an attractive organ for delivery of
vaccines.118 The top layer of the skin consists of the stratum
corneum, an effective barrier preventing penetration of foreign
molecules with molecular weights larger than 500 Da.92 There-
fore invasive or minimally invasive methods are needed to
administer vaccines to the skin. Many epidermal vaccination
strategies are currently developed, some of them based on pow-
der vaccine formulations and devices. The aim is to deliver
antigen directly into the epidermis because of the presence of
an extensive immune network.20,119
Most preclinical studies with powder epidermal vaccination
were done with the Powder Ject device. It operates on com-
pressed helium to deliver powder vaccine into the epider-
mis..120 Powders used conventionally for delivery by epidermal
powder immunization (EPI) are spray dried with a suitable size
(20 to 70 mm) and density.121 There have been several pre-clin-
ical studies that performed epidermal powder delivery using
formulations that were spray freeze-dried.
The powder vaccines were immunogenic in animals when
delivered as an epidermal powder for influenza,121 hepatitis B
surface antigen 23 and diphtheria toxoid.23 Mice receiving influ-
enza vaccine through EPI (average particle size 46 mm) showed
approximately 3-fold higher serum Hemagglutination Inhibi-
tion (HI) titers compared with the liquid influenza vaccine
administered by i.m route. EPI in guinea pigs (average particle
size 40 mm), with powder hepatitis B surface antigen adsorbed
to alum elicited comparable serum IgG response to liquid via i.
m route. A phase I clinical trial with spray freeze-dried
influenza vaccine showed that inclusion of adjuvants might
improve the vaccine efficacy when delivered with PowderJect
device.121 Despite these encouraging results, it may be difficult
to efficiently deliver powders to the skin because the density of
spray freeze-dried particles is relatively low. The required
kinetic energy to penetrate the skin is difficult to achieve unless
more dense particles 101 for instance spray dried particles
(which are generally denser than spray freeze-dried particles)
or gold particles are used.
Oral delivery
Oral delivery of vaccines has always been an interesting alterna-
tive to parenteral injection because of its ease of administration,
higher compliance and low production cost. However, the hos-
tile environment of the gastrointestinal tract (GI) and oral tol-
erance are major obstacles associated with oral vaccine
delivery.122-124 A study from Xiang et al. 125 reported that posi-
tively charged particles with a size of less than 5 mm can prefer-
entially enter Peyer’s patch of the small intestine and maybe
transported to antigen presenting cells. Nevertheless, other
authors found that a broader size range of less than 10 mm was
also suitable to elicit a good mucosal immune response.126 To
negate the destructive effect of the GI tract, enteric coating pol-
ymers are used as a delivery vehicle for oral spray dried vac-
cines.127 These include Eudragit S 100, L 100, cellulose acetate
phthalate and hydroxyl propyl methyl cellulose acetate succi-
nate (HPMC AS). Pastor et al. 59 studied a spray dried powder
heat inactivated cholera vaccine (particle size 6.0 mm), which
was given orally. Rats showed serum IgG responses with pow-
der vaccine suspension comparable to liquid suspension, when
administered by oral gavage. Another study 94 demonstrated
the thermostability of the cholera vaccine powder with no loss
in antigenicity (either with or without alginate), when stored at
40 C for 9 months (liquid vaccine control absent). Shastri
et al. 128 formulated an oral whole inactivated influenza vaccine
powder with Eudragit and trehalose (particle size between 1
and 6 mm). After oral administration (with 20 mg vaccine) in
mice, antigen specific immunoglobulins were induced and pro-
tection was demonstrated against a viral challenge when com-
pared with na€ıve mice controls. Another study reported
formulation of enteric coated spray dried microparticles con-
taining a tumor cell lysate against breast cancer 129 and admin-
istered as oral suspension in mice followed by tumor challenge.
It was observed that vaccinated mice developed significantly
smaller tumors compared with naive controls. Oral powder
vaccine enables tableting or granulation and thus facilitate stor-
age and transport. This could be of immense potential for mass
vaccination. Thus, delivery of vaccine powder by the oral route
is promising, but the only known licensed dry oral vaccine is
Vivotif, based on lyophilized live attenuated Salmonella typhi.
Challenges
Aside from the clear benefits of spray dried vaccines, several
challenges still need to be overcome before spray dried vaccines
can be marketed for commercial use. A successful marketed
spray dried vaccine would require a commercial scale setup.
Since spray drying is a continuous process, it can be readily





































scaled up by adjusting parameters of an individual production
unit. Depending on the batch size (that needs to be atomized
and dried), an increased thermodynamic input would be
needed to remove the additional solvent to produce a dried
powder matching the profile from the laboratory or pilot scale
unit. Therefore, extensive engineering would be required to
ensure that the dried vaccine product created at higher produc-
tion rates, meets the properties of the initially designed product.
Zhu et al. 12 developed a stable spray dried recombinant influ-
enza vaccine and scaled it up, producing 3 consistent batches of
»50 g on a pilot scale dryer. In past, a commercial spray dried
inhaled insulin Exubera was marketed by Pfizer for treatment
of Type 1 and Type 2 diabetes, but was withdrawn from the
market for reason unrelated to spray drying manufacturing.
Thus, scale-up of spray-dried vaccine is challenging but feasible
with additional considerations.
Asceptic process is essential for producing vaccines meant
for administration via parenteral route. Terminal sterilization
of spray dried vaccine by irradiation is an option, however it
may adversely affect the structure and activity of the product.
Scherlieb et al. 130 showed that by using a formulation contain-
ing chitosan and glycyrrhizinic acid with trehalose matrix for a
spray dried influenza A (H1N1) vaccine, terminal irradiation is
feasible. With the current technology sterile spray dried prod-
uct without post production sterilization is not achievable. Yet,
the emerging availability of asceptic spray drying technology
and additional practical experience would help extending spray
drying of vaccines to the commercial domain.
With the current technology, powder filling and accurate
dosing is challenging when compared with lyophilized vaccines,
which are accurately dosed as liquid before drying. The formu-
lation choice, powder handling procedures and flow properties
of the powder play an important role in dose distribution. It is
necessary to handle powder under control humidity conditions
to avoid any unwanted moisture uptake. Additional consider-
ation are required when handling vaccine powder containing
hygroscopic excipients (e.g., sorbitol, citric acid). Despite the
challenges, it is possible to achieve consistent powder dosing.
Exubera, a spray dried insulin was filled into 1–3 mg dose
containers on a commercial scale.
Future perspectives
Spray drying is a promising platform for drying vaccines. The
growing scientific interest in the field of particle engineering
and new nano and micro technologies would add to the
advancement of spray drying and needle free approaches for
vaccination. The current pharmaceutical drying technology for
vaccines is constructed around freeze drying. However, the
recent advances with aseptic spray drying of biopharmaceuti-
cals 131 has attracted a strong interest from the industry to
expand spray drying process for vaccines. For future expansion
in this field, one needs to address concerns regarding scaling
up, regulatory, and biosafety (and legislation) aspects. The
potential of spray dried vaccines to be stored and transported
outside the cold chain would simplify vaccine delivery to
remote areas and reduce the economic burden of vaccination
programs. Within the next 5 years, the results from clinical
studies and evidence from pharmaceutical production would
clarify the position of spray drying as a viable competitor to
conventional drying method for vaccines.
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
References
[1] Kumru OS, Joshi SB, Smith DE, Middaugh CR, Prusik T, Volkin
DB. Vaccine instability in the cold chain: Mechanisms, analysis and
formulation strategies. Biologicals. 2014;42(5):237–59. doi:10.1016/
j.biologicals.2014.05.007. PMID:24996452
[2] Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR.
Thermal stability of vaccines. J Pharm Sci. 2003;92(2):218–31.
doi:10.1002/jps.10296. PMID:12532371
[3] Zaffran M. Vaccine transport and storage: Environmental chal-
lenges. Dev Biol Stand. 1996;87:9–17. PMID:8853997
[4] Chen D, Kristensen D. Opportunities and challenges of developing
thermostable vaccines. Expert Rev Vaccines. 2009;8(5):547–57.
doi:10.1586/erv.09.20. PMID:19397412
[5] Organization WHO. Monitoring vaccine wastage at country level:
Guidelines for programmme managers 2005. http://www.who.int/
iris/handle/10665/68463
[6] Maltesen MJ, van de Weert M. Drying methods for protein phar-
maceuticals. Drug Discov Today Technol. 2008;5(2-3):e81–8.
doi:10.1016/j.ddtec.2008.11.001. PMID:24981095
[7] Geeraedts F, Saluja V, ter Veer W, Amorij JP, Frijlink HW, Wil-
schut J, Hinrichs WL, Huckriede A. Preservation of the immunoge-
nicity of dry-powder influenza H5N1 whole inactivated virus
vaccine at elevated storage temperatures. AAPS J. 2010;12(2):215–
22. doi:10.1208/s12248-010-9179-z. PMID:20195930
[8] Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL.
Development of stable influenza vaccine powder formulations:
Challenges and possibilities. Pharm Res. 2008;25(6):1256–73.
doi:10.1007/s11095-008-9559-6. PMID:18338241
[9] Adams G. The principles of freeze-drying. Methods Mol Biol.
2007;368:15–38. doi:10.1007/978-1-59745-362-2_2. PMID:18080460
[10] Greb E. Is spray drying a viable alternative to lyophilization? Equip-
ment and Processing Report; 2009. Epub Dec 16, 2009.
[11] Kanojia G, Willems GJ, Frijlink HW, Kersten GF, Soema PC,
Amorij JP. A Design of Experiment approach to predict product
and process parameters for a spray dried influenza vaccine. Int J
Pharm. 2016;511(2):1098–111. doi:10.1016/j.ijpharm.2016.08.022.
PMID:27523619
[12] Zhu C, Shoji Y, McCray S, Burke M, Hartman CE, Chichester JA,
Breit J, Yusibov V, Chen D, Lal M. Stabilization of HAC1 influenza
vaccine by spray drying: Formulation development and process
scale-up. Pharm Res. 2014;31:3006–18. doi:10.1007/s11095-014-
1394-3. PMID:24858396
[13] Roy I, Gupta MN. Freeze-drying of proteins: Some emerging
concerns. Biotechnol Appl Biochem. 2004;39(Pt 2):165–77.
doi:10.1042/BA20030133. PMID:15032737
[14] Katja S. Spray drying of protein precipitates and evaluation of the
nano spray dryer B-90 [Dissertation]. LMU Munich; 2011.
[15] Vehring R. Pharmaceutical particle engineering via spray drying.
Pharm Res. 2008;25(5):999–1022. doi:10.1007/s11095-007-9475-1.
PMID:18040761
[16] Masters K. Spray drying handbook. 5th ed. Burnt Mill, Harlow,
Essex, England New York: Longman Scientific & Technical; Wiley;
1991. xiv, 725.
[17] Gala RP, Popescu C, Knipp GT, McCain RR, Ubale RV, Addo R,
Bhowmik T, Kulczar CD, D’Souza MJ. Physicochemical and preclini-
cal evaluation of a novel buccal measles vaccine. AAPS PharmSci-
Tech. 2016;18(2):283–292. doi:10.1016/j.ijpharm.2015.04.053.
PMID:27357420
[18] Wanning S, Suverkrup R, Lamprecht A. Pharmaceutical spray
freeze drying. Int J Pharm. 2015;488(1-2):136–53. PMID:25900097





































[19] Maa YF, Zhao L, Payne LG, Chen D. Stabilization of alum-adju-
vanted vaccine dry powder formulations: Mechanism and applica-
tion. J Pharm Sci. 2003;92(2):319–32. doi:10.1002/jps.10294.
PMID:12532382
[20] Dean HJ, Chen D. Epidermal powder immunization against influ-
enza. Vaccine. 2004;23(5):681–6. doi:10.1016/j.vaccine.2004.06.041.
PMID:15542190
[21] Saluja V, Amorij JP, Kapteyn JC, de Boer AH, Frijlink HW, Hin-
richs WL. A comparison between spray drying and spray freeze
drying to produce an influenza subunit vaccine powder for inhala-
tion. J Control Release. 2010;144(2):127–33. doi:10.1016/j.
jconrel.2010.02.025. PMID:20219608
[22] Amorij JP, Saluja V, Petersen AH, Hinrichs WL, Huckriede A, Frij-
link HW. Pulmonary delivery of an inulin-stabilized influenza sub-
unit vaccine prepared by spray-freeze drying induces systemic,
mucosal humoral as well as cell-mediated immune responses in
BALB/c mice. Vaccine. 2007;25(52):8707–17. doi:10.1016/j.
vaccine.2007.10.035. PMID:17996993
[23] Maa YF, Shu C, Ameri M, Zuleger C, Che J, Osorio JE, Payne LG,
Chen D. Optimization of an alum-adsorbed vaccine powder formu-
lation for epidermal powder immunization. Pharm Res. 2003;20
(7):969–77. doi:10.1023/A:1024493719236. PMID:12880281
[24] Tonnis WF, Amorij JP, Vreeman MA, Frijlink HW, Kersten GF,
Hinrichs WL. Improved storage stability and immunogenicity of
hepatitis B vaccine after spray-freeze drying in presence of sugars.
Eur J Pharm Sci. 2014;55:36–45. doi:10.1016/j.ejps.2014.01.005.
PMID:24468629
[25] Mikszta JA, Sullivan VJ, Dean C, Waterston AM, Alarcon JB, Dek-
ker JP 3rd, Brittingham JM, Huang J, Hwang CR, Ferriter M, et al.
Protective immunization against inhalational anthrax: A compari-
son of minimally invasive delivery platforms. J Infect Dis. 2005;191
(2):278–88. doi:10.1086/426865. PMID:15609239
[26] Wang SH, Kirwan SM, Abraham SN, Staats HF, Hickey AJ. Stable dry
powder formulation for nasal delivery of anthrax vaccine. J Pharm Sci.
2012;101(1):31–47. doi:10.1002/jps.22742. PMID:21905034
[27] Huang J, D’Souza AJ, Alarcon JB, Mikszta JA, Ford BM, Ferriter
MS, Evans M, Stewart T, Amemiya K, Ulrich RG, et al. Protective
immunity in mice achieved with dry powder formulation and alter-
native delivery of plague F1-V vaccine. Clin Vaccine Immunol.
2009;16(5):719–25. doi:10.1128/CVI.00447-08. PMID:19261773
[28] Jovanovic N, Bouchard A, Hofland GW, Witkamp GJ, Crommelin
DJ, Jiskoot W. Stabilization of proteins in dry powder formulations
using supercritical fluid technology. Pharm Res. 2004;21(11):1955–
69. doi:10.1023/B:PHAM.0000048185.09483.e7. PMID:15587916
[29] Sievers RE, Karst U. Inventor Methods for fine particle formation
1997 June 17. Patent US5639441 A.
[30] Sievers RESPS, Carpenter JF. inventorSupercritical fluid-assisted nebu-
lization and bubble drying 2003 October 7. Patent US 6630121 B1.
[31] Cape SP, Villa JA, Huang ET, Yang TH, Carpenter JF, Sievers RE. Prepa-
ration of active proteins, vaccines and pharmaceuticals as fine powders
using supercritical or near-critical fluids. Pharm Res. 2008;25(9):1967–
90. doi:10.1007/s11095-008-9575-6. PMID:18581212
[32] Sellers SP, Clark GS, Sievers RE, Carpenter JF. Dry powders of sta-
ble protein formulations from aqueous solutions prepared using
supercritical CO(2)-assisted aerosolization. J Pharm Sci. 2001;90
(6):785–97. doi:10.1002/jps.1032. PMID:11357179
[33] Burger JL, Cape SP, Braun CS, McAdams DH, Best JA, Bhagwat P,
Pathak P, Rebits LG, Sievers RE. Stabilizing formulations for inhal-
able powders of live-attenuated measles virus vaccine. J Aerosol
Med Pulm drug deliv. 2008;21(1):25–34. doi:10.1089/
jamp.2007.0658. PMID:18518829
[34] Kissmann J, Ausar SF, Rudolph A, Braun C, Cape SP, Sievers RE,
Federspiel MJ, Joshi SB, Middaugh CR. Stabilization of measles
virus for vaccine formulation. Hum Vaccin. 2008;4(5):350–9.
doi:10.4161/hv.4.5.5863. PMID:18382143
[35] LeClair DA, Cranston ED, Xing Z, Thompson MR. Optimization of
spray drying conditions for yield, particle size and biological activity
of thermally stable viral vectors. Pharm Res. 2016;33(11):2763–76.
doi:10.1007/s11095-016-2003-4. PMID:27450412
[36] Grasmeijer N. Improving protein stabilization by spray drying
[PhD thesis]. University of Groningen; 2016.
[37] Maa YF, Prestrelski SJ. Biopharmaceutical powders: Particle formation
and formulation considerations. Curr Pharm Biotechnol. 2000;1
(3):283–302. doi:10.2174/1389201003378898. PMID:11469385
[38] Webb SD, Golledge SL, Cleland JL, Carpenter JF, Randolph TW.
Surface adsorption of recombinant human interferon-gamma in
lyophilized and spray-lyophilized formulations. J Pharm Sci.
2002;91(6):1474–87. doi:10.1002/jps.10135. PMID:12115847
[39] Mumenthaler M, Hsu CC, Pearlman R. Feasibility study on spray-
drying protein pharmaceuticals: Recombinant human growth hor-
mone and tissue-type plasminogen activator. Pharm Res. 1994;11
(1):12–20. doi:10.1023/A:1018929224005. PMID:8140042
[40] Ohtake S, Martin RA, Yee L, Chen D, Kristensen DD, Lechuga-Bal-
lesteros D, Truong-Le V. Heat-stable measles vaccine produced by
spray drying. Vaccine. 2010;28(5):1275–84. doi:10.1016/j.
vaccine.2009.11.024. PMID:19944152
[41] Stahl K, Claesson M, Lilliehorn P, Linden H, Backstrom K. The effect
of process variables on the degradation and physical properties of
spray dried insulin intended for inhalation. Int J Pharm. 2002;233(1-
2):227–37. doi:10.1016/S0378-5173(01)00945-0. PMID:11897427
[42] Maltesen MJ, Bjerregaard S, Hovgaard L, Havelund S, van de Weert
M. Quality by design - Spray drying of insulin intended for inhala-
tion. Eur J Pharm Biopharm. 2008;70(3):828–38. doi:10.1016/j.
ejpb.2008.07.015. PMID:18755270
[43] Rabbani NR, Seville PC. The influence of formulation components
on the aerosolisation properties of spray-dried powders. J Control
Release. 2005;110(1):130–40. doi:10.1016/j.jconrel.2005.09.004.
PMID:16226334
[44] Wong YL, Sampson S, Germishuizen WA, Goonesekera S, Capo-
netti G, Sadoff J, Bloom BR, Edwards D. Drying a tuberculosis vac-
cine without freezing. Proc Natl Acad Sci U S A. 2007;104(8):2591–
5. doi:10.1073/pnas.0611430104. PMID:17299039
[45] Lin WH, Griffin DE, Rota PA, Papania M, Cape SP, Bennett D,
Quinn B, Sievers RE, Shermer C, Powell K, et al. Successful respira-
tory immunization with dry powder live-attenuated measles virus
vaccine in rhesus macaques. Proc Natl Acad Sci U S A. 2011;108
(7):2987–92. doi:10.1073/pnas.1017334108. PMID:21282608
[46] Lovalenti PM, Anderl J, Yee L, Nguyen V, Ghavami B, Ohtake S, Saxena
A, Voss T, Truong-Le V. Stabilization of live attenuated influenza vac-
cines by freeze drying, spray drying, and foam drying. Pharm Res.
2016;33:1144–60. doi:10.1007/s11095-016-1860-1. PMID:26818839
[47] Sou T, Morton DA, Williamson M, Meeusen EN, Kaminskas LM,
McIntosh MP. Spray-Dried influenza antigen with trehalose and
leucine produces an aerosolizable powder vaccine formulation that
induces strong systemic and mucosal immunity after pulmonary
administration. J Aerosol Med Pulm Drug Deliv. 2015;28:361–71.
doi:10.1089/jamp.2014.1176. PMID:25714115
[48] Garcia-Contreras L, Wong YL, Muttil P, Padilla D, Sadoff J, Derousse J,
GermishuizenWA, Goonesekera S, Elbert K, Bloom BR, et al. Immuni-
zation by a bacterial aerosol. Proc Natl Acad Sci U S A. 2008;105
(12):4656–60. doi:10.1073/pnas.0800043105. PMID:18344320
[49] Jin TH, Tsao E, Goudsmit J, Dheenadhayalan V, Sadoff J. Stabiliz-
ing formulations for inhalable powders of an adenovirus 35-vec-
tored tuberculosis (TB) vaccine (AERAS-402). Vaccine. 2010;28
(27):4369–75. doi:10.1016/j.vaccine.2010.04.059. PMID:20444437
[50] Tyne AS, Chan JG, Shanahan ER, Atmosukarto I, Chan HK,
Britton WJ, West NP. TLR2-targeted secreted proteins from
Mycobacterium tuberculosis are protective as powdered pulmo-
nary vaccines. Vaccine. 2013;31(40):4322–9. doi:10.1016/j.
vaccine.2013.07.022. PMID:23880366
[51] Lu D, Garcia-Contreras L, Xu D, Kurtz SL, Liu J, Braunstein M,
McMurray DN, Hickey AJ. Poly (lactide-co-glycolide) microspheres
in respirable sizes enhance an in vitro T cell response to recombi-
nant Mycobacterium tuberculosis antigen 85B. Pharm Res. 2007;24
(10):1834–43. doi:10.1007/s11095-007-9302-8. PMID:17657598
[52] Lu D, Garcia-Contreras L, Muttil P, Padilla D, Xu D, Liu J, Braun-
stein M, McMurray DN, Hickey AJ. Pulmonary immunization
using antigen 85-B polymeric microparticles to boost tuberculosis





































immunity. AAPS J. 2010;12(3):338–47. doi:10.1208/s12248-010-
9193-1. PMID:20422340
[53] Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon JK, Wang
C, Hickey AJ, Edwards D. Immunization of guinea pigs with novel
hepatitis B antigen as nanoparticle aggregate powders administered
by the pulmonary route. AAPS J. 2010;12(3):330–7. doi:10.1208/
s12248-010-9192-2. PMID:20419360
[54] Tawde SA, Chablani L, Akalkotkar A, D’Souza MJ. Evaluation of
microparticulate ovarian cancer vaccine via transdermal route of
delivery. J Control Release. 2016;235:147–54. doi:10.1016/j.
jconrel.2016.05.058. PMID:27238440
[55] Saboo S, Tumban E, Peabody J, Wafula D, Peabody DS, Chack-
erian B, Muttil P. Optimized formulation of a thermostable
spray-dried virus-like particle vaccine against human papilloma-
virus. Mol Pharm. 2016;13(5):1646–55. doi:10.1021/acs.
molpharmaceut.6b00072. PMID:27019231
[56] Peabodya J, Muttil P, Chackeriana B, Tumban E. Characterization
of a spray-dried candidate HPV L2-VLP vaccine stored for multiple
years at room temperature. Papillomavirus Res. 2017;10(3):116–20.
doi:10.1016/j.pvr.2017.03.004
[57] LeClair DA, Cranston ED, Xing Z, Thompson MR. Evaluation of
excipients for enhanced thermal stabilization of a human type 5
adenoviral vector through spray drying. Int J Pharm. 2016;506(1-
2):289–301. doi:10.1016/j.ijpharm.2016.04.067. PMID:27130366
[58] Afkhami S, LeClair DA, Haddadi S, Lai R, Toniolo SP, Ertl HC,
Cranston ED, Thompson MR, Xing Z. Spray dried human and
chimpanzee adenoviral-vectored vaccines are thermally stable and
immunogenic in vivo. Vaccine. 2017;35:2916–24. doi:10.1016/j.
vaccine.2017.04.026. PMID:28438408
[59] Pastor M, Esquisabel A, Marquinez I, Talavera A, Pedraz JL. Cellu-
lose acetate phthalate microparticles containing Vibrio cholerae:
Steps toward an oral cholera vaccine. J Drug Target. 2014;22
(6):478–87. doi:10.3109/1061186X.2014.888071. PMID:24731056
[60] Ano G, Esquisabel A, Pastor M, Talavera A, Cedre B, Fernandez S,
Sifontes S, Aranguren Y, Falero G, Garcıa L, et al. A new oral vac-
cine candidate based on the microencapsulation by spray-drying of
inactivated Vibrio cholerae. Vaccine. 2011;29(34):5758–64.
doi:10.1016/j.vaccine.2011.05.098. PMID:21683110
[61] Muttil P, Pulliam B, Garcia-Contreras L, Fallon JK, Wang C, Hickey
AJ, Edwards DA. Pulmonary immunization of guinea pigs with
diphtheria CRM-197 antigen as nanoparticle aggregate dry powders
enhance local and systemic immune responses. AAPS J. 2010;12
(4):699–707. doi:10.1208/s12248-010-9229-6. PMID:20878294
[62] Jones RM, Burke M, Dubose D, Chichester JA, Manceva S, Horsey
A, Streatfield SJ, Breit J, Yusibov V. Stability and pre-formulation
development of a plant-produced anthrax vaccine candidate. Vac-
cine. 2017;35(41):5463–5470. doi:10.1016/j.vaccine.2016.12.009
[63] Chen D, Kapre S, Goel A, Suresh K, Beri S, Hickling J, Jensen J, Lal
M, Preaud JM, Laforce M, et al. Thermostable formulations of a
hepatitis B vaccine and a meningitis A polysaccharide conjugate
vaccine produced by a spray drying method. Vaccine. 2010;28
(31):5093–9. doi:10.1016/j.vaccine.2010.04.112. PMID:20478345
[64] Anish C, Upadhyay AK, Sehgal D, Panda AK. Influences of process
and formulation parameters on powder flow properties and immu-
nogenicity of spray dried polymer particles entrapping recombinant
pneumococcal surface protein A. Int J Pharm. 2014;466(1-2):198–
210. doi:10.1016/j.ijpharm.2014.03.025. PMID:24631054
[65] Kunda NK, Alfagih IM, Miyaji EN, Figueiredo DB, Goncalves VM,
Ferreira DM, Dennison SR, Somavarapu S, Hutcheon GA, Saleem
IY. Pulmonary dry powder vaccine of pneumococcal antigen loaded
nanoparticles. Int J Pharm. 2015;495(2):903–12. doi:10.1016/j.
ijpharm.2015.09.034. PMID:26387622
[66] Grasmeijer N, Stankovic M, de Waard H, Frijlink HW, Hinrichs WL.
Unraveling protein stabilization mechanisms: Vitrification and water
replacement in a glass transition temperature controlled system.
Biochim Biophys Acta. 2013;1834(4):763–9. doi:10.1016/j.
bbapap.2013.01.020. PMID:23360765
[67] Crowe JH, Crowe LM, Chapman D. Preservation of membranes in
anhydrobiotic organisms: The role of trehalose. Science. 1984;223
(4637):701–3. doi:10.1126/science.223.4637.701. PMID:17841031
[68] Schule S, Schulz-Fademrecht T, Garidel P, Bechtold-Peters K, Frieb W.
Stabilization of IgG1 in spray-dried powders for inhalation. Eur J Pharm
Biopharm. 2008;69(3):793–807. doi:10.1016/j.ejpb.2008.02.010. PMID:
18477504
[69] Aschenbrenner M, Grammueller E, Kulozik U, Foerst P. The contri-
bution of the inherent restricted mobility of glassy sugar matrices to
the overall stability of freeze-dried bacteria determined by low-reso-
lution solid-state 1H-NMR. Food Bioproc Tech. 2014;7(4):1012–24.
doi:10.1007/s11947-013-1095-7
[70] Carpenter JF, Crowe JH. An infrared spectroscopic study of the
interactions of carbohydrates with dried proteins. Biochemistry.
1989;28(9):3916–22. doi:10.1021/bi00435a044. PMID:2526652
[71] Kunda NK, Wafula D, Tram M, Wu TH, Muttil P. A stable live
bacterial vaccine. Eur J Pharm Biopharm.2016;103:109–17.
doi:10.1016/j.ejpb.2016.03.027. PMID:27020530
[72] Tonnis WF, Mensink MA, de Jager A, van der Voort Maarschalk K,
Frijlink HW, Hinrichs WL. Size and molecular flexibility of sugars
determine the storage stability of freeze-dried proteins. Mol Pharm.
2015;12(3):684–94. doi:10.1021/mp500423z. PMID:25581526
[73] Bam NB, Cleland JL, Yang J, Manning MC, Carpenter JF, Kelley RF,
Randolph TW. Tween protects recombinant human growth hor-
mone against agitation-induced damage via hydrophobic interac-
tions. J Pharm Sci. 1998;87(12):1554–9. doi:10.1021/js980175v.
PMID:10189266
[74] Jones LS, Cipolla D, Liu J, Shire SJ, Randolph TW. Investigation of
protein-surfactant interactions by analytical ultracentrifugation and
electron paramagnetic resonance: The use of recombinant human
tissue factor as an example. Pharm Res. 1999;16(6):808–12.
doi:10.1023/A:1018809632395. PMID:10397598
[75] Kreilgaard L, Frokjaer S, Flink JM, Randolph TW, Carpenter JF. Effects
of additives on the stability of recombinant human factor XIII during
freeze-drying and storage in the dried solid. Arch Biochem Biophys.
1998;360(1):121–34. doi:10.1006/abbi.1998.0948. PMID:9826437
[76] Prince AM, Stephan W, Kotitschke R, Brotman B. Inactivation of
hepatitis B and non-A, non-B viruses by combined use of Tween 80,
beta-propiolactone, and ultraviolet irradiation. Thromb Haemost.
1983;50(2):534–6. doi:10.1006/abbi.1997.0111. PMID:6415846
[77] Cherepova N, Veljanov D. Effect of sorbitan monolaurate polyox-
yalkylene (Tween 20) on the ultrastructure of some bacteria. Cyto-
bios. 1994;80(322):179–85. PMID:7539732
[78] Newman JF, Tirrell S, Ullman C, Piatti PG, Brown F. Stabilising oral
poliovaccine at high ambient temperatures. Dev Biol Stand.
1996;87:103–11. PMID:8854007
[79] Chen CH, Wu R, Roth LG, Guillot S, Crainic R. Elucidating mecha-
nisms of thermostabilization of poliovirus by D2O and MgCl2.
Arch Biochem Biophys. 1997;342(1):108–16. PMID:9185619
[80] Erk I, Huet JC, Duarte M, Duquerroy S, Rey F, Cohen J, Lepault J. A
zinc ion controls assembly and stability of the major capsid protein
of rotavirus. J Virol. 2003;77(6):3595–601. doi:10.1128/
JVI.77.6.3595-3601.2003. PMID:12610135
[81] Shirley JA, Beards GM, Thouless ME, Flewett TH. The influence of
divalent cations on the stability of human rotavirus. Arch Virol.
1981;67(1):1–9. doi:10.1007/BF01314596. PMID:6263223
[82] Turnbull AE, Skulimowski A, Smythe JA, Alexander IE. Adeno-asso-
ciated virus vectors show variable dependence on divalent cations for
thermostability: Implications for purification and handling. Hum
Gene Ther. 2000;11(4):629–35. doi:10.1089/10430340050015815.
PMID:10724041
[83] Duddu SP, Dal Monte PR. Effect of glass transition temperature on
the stability of lyophilized formulations containing a chimeric
therapeutic monoclonal antibody. Pharm Res. 1997;14(5):591–5.
doi:10.1023/A:1012144810067. PMID:9165528
[84] Sarciaux JM, Hageman MJ. Effects of bovine somatotropin (rbSt)
concentration at different moisture levels on the physical stability
of sucrose in freeze-dried rbSt/sucrose mixtures. J Pharm Sci.
1997;86(3):365–71. doi:10.1021/js960217k. PMID:9050807
[85] Walters RH, Bhatnagar B, Tchessalov S, Izutsu K, Tsumoto K,
Ohtake S. Next generation drying technologies for pharmaceutical
applications. J Pharm Sci. 2014;103(9):2673–95. doi:10.1002/
jps.23998. PMID:24916125





































[86] Calcott P. Implementation of quality by design in vaccine development:
BioProcess international; 2013 [cited 2013 February].Web Article.
[87] Administration. UFaD. Guidance for industry: Q10 pharmaceutical
cGMP regulations, US Department of Health and Human Service.
Rockville (MD): FDA; September, 2006. FDA Guideline.
[88] Rathore AS. Roadmap for implementation of quality by design
(QbD) for biotechnology products. Trends Biotechnol. 2009;27
(9):546–53. doi:10.1016/j.tibtech.2009.06.006. PMID:19647883
[89] Rathore AS, Winkle H. Quality by design for biopharmaceuticals.
Nat Biotechnol. 2009;27(1):26–34. doi:10.1038/nbt0109-26.
PMID:19131992
[90] Haas J, Franklin A, Houser M, Maraldo D, Mikola M, Ortiz R, Sulli-
van E, Otero JM. Implementation of QbD for the development of a
vaccine candidate. Vaccine. 2014;32(24):2927–30. doi:10.1016/j.
vaccine.2014.02.028. PMID:24598725
[91] group Ma, Cape S, Chaudhari A, Vaidya V, Mulay R, Agar-
khedkar S, Shermer C, Collins M, Anderson R, Agarkhedkar S,
et al. Safety and immunogenicity of dry powder measles vaccine
administered by inhalation: A randomized controlled Phase I
clinical trial. Vaccine. 2014;32(50):6791–7. doi:10.1016/j.
vaccine.2014.09.071. PMID:25446830
[92] Weniger BG, Papania MJ. 61 - Alternative vaccine delivery methods
A2 - Plotkin, Stanley A. In: Orenstein WA, Offit PA, editors. Vac-
cines (Sixth Edition). London: W.B. Saunders; 2013. p. 1200–31.
[93] Satti I, Meyer J, Harris SA, Manjaly Thomas ZR, Griffiths K,
Antrobus RD, Rowland R, Ramon RL, Smith M, Sheehan S, et
al. Safety and immunogenicity of a candidate tuberculosis vac-
cine MVA85A delivered by aerosol in BCG-vaccinated healthy
adults: A phase 1, double-blind, randomised controlled trial.
Lancet Infect Dis. 2014;14(10):939–46. doi:10.1016/S1473-3099
(14)70845-X. PMID:25151225
[94] Pastor M, Esquisabel A, Talavera A, Ano G, Fernandez S, Cedre
B, Infante JF, Callico A, Pedraz JL. An approach to a cold chain
free oral cholera vaccine: in vitro and in vivo characterization
of Vibrio cholerae gastro-resistant microparticles. Int J Pharm.
2013;448(1):247–58. doi:10.1016/j.ijpharm.2013.02.057. PMID:
23518363
[95] Minne A, Louahed J, Mehauden S, Baras B, Renauld JC, Vanb-
ever R. The delivery site of a monovalent influenza vaccine
within the respiratory tract impacts on the immune response.
Immunology. 2007;122(3):316–25. doi:10.1111/j.1365-2567.2007.
02641.x. PMID:17521369
[96] Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med.
2005;11(4 Suppl):S45–53. doi:10.1038/nm1213. PMID:15812489
[97] Thomas C, Gupta V, Ahsan F. Particle size influences the immune
response produced by hepatitis B vaccine formulated in inhalable
particles. Pharm Res. 2010;27(5):905–19. doi:10.1007/s11095-010-
0094-x. PMID:20232117
[98] Lu D, Hickey AJ. Pulmonary vaccine delivery. Expert Rev Vaccines.
2007;6(2):213–26. doi:10.1586/14760584.6.2.213. PMID:17408371
[99] Sou T, Meeusen EN, de Veer M, Morton DA, Kaminskas LM,
McIntosh MP. New developments in dry powder pulmonary vac-
cine delivery. Trends Biotechnol. 2011;29(4):191–8. doi:10.1016/j.
tibtech.2010.12.009. PMID:21255854
[100] Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug
delivery. Expert Opin Drug Deliv. 2004;1(1):67–86. doi:10.1517/
17425247.1.1.67. PMID:16296721
[101] Amorij JP, Hinrichs W, Frijlink HW, Wilschut JC, Huckriede A. Nee-
dle-free influenza vaccination. Lancet Infect Dis. 2010;10(10):699–711.
doi:10.1016/S1473-3099(10)70157-2. PMID:20883966
[102] de Boer AH, Hagedoorn P, Westerman EM, Le Brun PP, Heijerman
HG, Frijlink HW. Design and in vitro performance testing of multi-
ple air classifier technology in a new disposable inhaler concept
(Twincer) for high powder doses. Eur J Pharm. 2006;28(3):171–8.
doi:10.1016/j.ejps.2005.11.013. PMID:16650739
[103] Hoppentocht M, Akkerman OW, Hagedoorn P, Alffenaar JW, van der
Werf TS, Kerstjens HA, Frijlink HW, de Boer AH. Tolerability and
pharmacokinetic evaluation of inhaled dry powder tobramycin free base
in non-cystic fibrosis bronchiectasis patients. PloS One. 2016;11(3):
e0149768. doi:10.1371/journal.pone.0149768. PMID:26959239
[104] Jabbal-Gill I. Nasal vaccine innovation. J Drug Target. 2010;18
(10):771–86. doi:10.3109/1061186X.2010.523790. PMID:21047271
[105] Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr
C, Steffen R. Use of the inactivated intranasal influenza vaccine and
the risk of Bell’s palsy in Switzerland. New Engl J Med. 2004;350
(9):896–903. doi:10.1056/NEJMoa030595. PMID:14985487
[106] Tafaghodi M, Abolghasem Sajadi Tabassi S, Jaafari MR, Zakavi SR,
Momen-Nejad M. Evaluation of the clearance characteristics of var-
ious microspheres in the human nose by gamma-scintigraphy. Int J
Pharm. 2004;280(1-2):125–35. doi:10.1016/j.ijpharm.2004.05.009.
PMID:15265553
[107] Vidgren MT, Kublik H. Nasal delivery systems and their effect on
deposition and absorption. Adv Drug Deliv Rev. 1998;29(1-2):157–
77. doi:10.1016/S0169-409X(97)00067-7. PMID:10837586
[108] Newman SP, Pitcairn GR, Dalby RN. Drug delivery to the nasal cav-
ity: In vitro and in vivo assessment. Crit Rev Ther Drug Carrier
Syst. 2004;21(1):21–66. doi:10.1615/CritRevTherDrugCarrierSyst.
v21.i1.20. PMID:15099184
[109] Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive
drug delivery: Background, applications, trends and future perspec-
tives. Adv Drug Deliv Rev. 2005;57(11):1640–65. doi:10.1016/j.
addr.2005.07.009. PMID:16182408
[110] Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy
CJ, Ulrich RG, Sullivan VJ. Intranasal administration of dry powder
anthrax vaccine provides protection against lethal aerosol spore
challenge. Hum Vaccin. 2007;3(3):90–3. doi:10.4161/hv.3.3.4011.
PMID:17375001
[111] Huang J, Garmise RJ, Crowder TM, Mar K, Hwang CR, Hickey AJ,
Mikszta JA, Sullivan VJ. A novel dry powder influenza vaccine
and intranasal delivery technology: Induction of systemic and
mucosal immune responses in rats. Vaccine. 2004;23(6):794–801.
doi:10.1016/j.vaccine.2004.06.049. PMID:15542204
[112] Garmise RJ, Staats HF, Hickey AJ. Novel dry powder preparations of
whole inactivated influenza virus for nasal vaccination. AAPSPharmSci-
Tech. 2007;8(4):E81. doi:10.1208/pt0804081. PMID:18181542
[113] Papania MJJJB, Bagley MC, Friets EM, Knaus DA. inventor; The
United States Of America, As Represented By The Secretary,
Department Of Health And Human Services, Creare Llc,, assignee.
Nasal aerosol delivery system 2011.
[114] Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug
delivery. J Control Release. 2011;153(2):106–16. doi:10.1016/j.
jconrel.2011.01.027. PMID:21300115
[115] Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G,
Amorij JP. Buccal and sublingual vaccine delivery. J Control
Release. 2014;190:580–92. doi:10.1016/j.jconrel.2014.05.060.
PMID:24911355
[116] Kraan H, van der Stel W, Kersten G, Amorij JP. Alternative administra-
tion routes and delivery technologies for polio vaccines. Expert Rev Vac-
cines. 2016;15(8):1029–40. doi:10.1586/14760584.2016.1158650. PMID:
26912100
[117] Ubale RV, D’Souza MJ, Infield DT, McCarty NA, Zughaier SM.
Formulation of meningococcal capsular polysaccharide vaccine-
loaded microparticles with robust innate immune recognition. J
Microencapsul. 2013;30(1):28–41. doi:10.3109/02652048.2012.
692402. PMID:22657751
[118] Mitragotri S. Immunization without needles. Nat Rev Immunol.
2005;5(12):905–16. doi:10.1038/nri1728. PMID:16239901
[119] Chen D, Burger M, Chu Q, Endres R, Zuleger C, Dean H,
Payne LG. Epidermal powder immunization: Cellular and
molecular mechanisms for enhancing vaccine immunogenicity.
Virus Res. 2004;103(1-2):147–53. doi:10.1016/j.virusres.2004.02.
027. PMID:15163503
[120] Dean HJ. Epidermal delivery of protein and DNA vaccines. Expert
Opin Drug Deliv. 2005;2(2):227–36. doi:10.1517/17425247.2.2.227.
PMID:16296750
[121] Chen D, Endres R, Maa YF, Kensil CR, Whitaker-Dowling P,
Trichel A, Youngner JS, Payne LG. Epidermal powder immuni-
zation of mice and monkeys with an influenza vaccine. Vaccine.
2003;21(21-22):2830–6. doi:10.1016/S0264-410X(03)00175-0.
PMID:12798624





































[122] Lycke N. Recent progress in mucosal vaccine development: Poten-
tial and limitations. Nat Rev Immunol. 2012;12(8):592–605.
doi:10.1038/nri3251. PMID:22828912
[123] Akande J, Yeboah KG, Addo RT, Siddig A, Oettinger CW, D’Souza
MJ. Targeted delivery of antigens to the gut-associated lymphoid
tissues: 2. Ex vivo evaluation of lectin-labelled albumin micro-
spheres for targeted delivery of antigens to the M-cells of the Peyer’s
patches. J Microencapsul. 2010;27(4):325–36. doi:10.3109/
02652040903191834. PMID:20055749
[124] Wilkhu J, McNeil SE, Kirby DJ, Perrie Y. Formulation design
considerations for oral vaccines. Ther Deliv. 2011;2(9):1141–64.
doi:10.4155/tde.11.82. PMID:22833911
[125] Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mot-
tram PL, Plebanski M. Pathogen recognition and development of
particulate vaccines: Does size matter? Methods. 2006;40(1):1–9.
doi:10.1016/j.ymeth.2006.05.016. PMID:16997708
[126] Hori M, Onishi H, Machida Y. Evaluation of Eudragit-coated chitosan
microparticles as an oral immune delivery system. Int J Pharm.
2005;297(1-2):223–34. doi:10.1016/j.ijpharm.2005.04.008. PMID:
15885938
[127] Chablani L, Tawde SA, D’Souza MJ. Spray-dried microparticles: A
potential vehicle for oral delivery of vaccines. J Microencapsul.
2012;29:388–97. doi:10.3109/02652048.2011.651503. PMID:22283700
[128] Shastri PN, Kim MC, Quan FS, D’Souza MJ, Kang SM. Immunoge-
nicity and protection of oral influenza vaccines formulated into
microparticles. J Pharm Sci. 2012;101(10):3623–35. doi:10.1002/
jps.23220. PMID:22711602
[129] Chablani L, Tawde SA, Akalkotkar A, D’Souza C, Selvaraj P,
D’Souza MJ. Formulation and evaluation of a particulate oral breast
cancer vaccine. J Pharm Sci. 2012;101(10):3661–71. doi:10.1002/
jps.23275. PMID:22828873
[130] Scherliess R, Ajmera A, Dennis M, Carroll MW, Altrichter J, Silman NJ,
Scholz M, Kemter K, Marriott AC. Induction of protective immunity
against H1N1 influenza A(H1N1)pdm09 with spray-dried and elec-
tron-beam sterilised vaccines in non-human primates. Vaccine. 2014;32
(19):2231–40. doi:10.1016/j.vaccine.2014.01.077. PMID:24631078
[131] Siew A. Exploring the use of aseptic spray drying in the manufac-
ture of biopharmaceutical injectables. Pharmaceutical Technology.
2016;40(7):24-27. http://www.pharmtech.com/exploring-use-asep
tic-spray-drying-manufacture-biopharmaceutical-injectables
2378 G. KANOJIA ET AL.
D
ow
nl
oa
de
d 
by
 [
U
ni
ve
rs
ite
it 
L
ei
de
n 
/ L
U
M
C
] 
at
 0
4:
14
 0
9 
Ja
nu
ar
y 
20
18
 
